Current Neuro-Oncology
Volume
26 Number 16
10 August 2024
Home > Publications > Current Neuro-Oncology > Volume 26, Year 2024 > Number 16, 10 August
Kurniawan T, Dwidanarti SR, Dhamiyati W, Ekaputra E, Meidania L,
Yanuarta SE, Choridah L.
Clinical
improvement of diffuse intrinsic pontine glioma treated with
radiation therapy concurrent with temozolomide: A case report.
Med
J Malaysia. 2024 Aug;79(Suppl 4):87-90. PMID:
39215422. Case report. ˍ
*Butler M, Mehra M, Chandasir A, Kaoutzani L, Vale FL.
Analysis
of the discontinuation and nonpublication of neurooncological
randomized clinical trials.
Neurooncol
Adv. 2024 Aug 1;6(1):vdae136. doi:
10.1093/noajnl/vdae136. PMID:
39211519. Observational study. ˍ
*Fang CS, Wang W, Schroff C, Movahed-Ezazi M, Vasudevaraja V,
Serrano J, Sulman EP, Golfinos JG, Orringer D, Galbraith K, Feng
Y, Snuderl M.
Racial
distribution of molecularly classified brain tumors.
Neurooncol
Adv. 2024 Aug 2;6(1):vdae135. doi:
10.1093/noajnl/vdae135. PMID:
39220243. Observational study. ˍ
*Harter PN, Weber KJ, Ricklefs FL, Drexler R, Schüller U,
Hack M, Hanke T, Dohmen H, Acker T, von Deimling A, Hasselblatt M,
Divé I, Unger K, Steinbach JP, Capper D, Ronellenfitsch MW.
Survival probability of epigenetically
defined IDH-wild-type glioblastoma without necrosis or vascular
proliferation.
Neurooncol
Adv. 2024 Aug 2;6(1):vdae138. doi:
10.1093/noajnl/vdae138. PMID:
39184173. Observational study. ˍ
Li B, Gao B, Zhu HJ, Luwor RB, Lu J, Zhang L, Kong B.
The
Prognostic Value of Preoperative Inflammatory Markers for
Pathological Grading of Glioma Patients.
Technol
Cancer Res Treat. 2024 Aug 5;23:15330338241273160. doi:
10.1177/15330338241273160. PMID:
39099463. Observational study. ˍ
Rilinger RG, Guo L, Sharma A, Volovetz J, Thompson NR, Grabowski
M, Lobbous M, Dhawan A.
Tumor-related
epilepsy in high-grade glioma: a large series survival analysis.
J
Neurooncol. 2024 Aug 5. doi:
10.1007/s11060-024-04787-z. PMID:
39102118. Observational study. ˍ
Cabezas-Camarero S, Pérez-Alfayate R, Polidura C,
Gómez-Ruiz MN, Gil-Martínez L, Casado-Fariñas
I, Bartolomé J, Pérez-Segura P.
Durable
benefit and slowdown in tumor growth dynamics with erdafitinib in
a FGFR3-TACC3 fusion-positive IDH-wild type
glioblastoma.
Neurooncol
Adv. 2024 Aug 6;6(1):vdae139. doi:
10.1093/noajnl/vdae139. PMID:
39211518. Case report. ˍ
Gillespie CS et al., INTERVAL-GB Collaborative; Neurology and
Neurosurgery Interest Group (NANSIG);
British Neurosurgical Trainee Research Collaborative (BNTRC).
Imaging timing after surgery for
glioblastoma: an evaluation of practice in Great Britain and
Ireland (INTERVAL-GB)- a multi-centre, cohort study.
J
Neurooncol. 2024 Aug 6. doi:
10.1007/s11060-024-04705-3. PMID:
39105956. Observational study. ˍ
Guo G, Zhang Z, Zhang J, Wang D, Xu S, Liu G, Gao Y, Mei J, Yan Z,
Zhao R, Wang M, Li T, Bu X.
Predicting
recurrent glioblastoma clinical outcome to immune checkpoint
inhibition and low-dose bevacizumab with tumor in situ fluid
circulating tumor DNA analysis.
Cancer
Immunol Immunother. 2024 Aug 6;73(10):193. doi:
10.1007/s00262-024-03774-7. PMID:
39105794. Interventional study. ˍ
Steininger J, Buszello C, Oertel R, Meinhardt M, Schmid S,
Engellandt K, Herold S, Stasik S, Ebrahimi A, Renner B, Thiede C,
Eyüpoglu IY, Schackert G, Beissert S, Meier F, Radke J,
Westphal D, Juratli TA.
Efficacy of
BRAF/MEK-inhibitor therapy for epithelioid glioblastoma with a
novel BRAFV600 mutation.
Acta
Neuropathol Commun. 2024 Aug 6;12(1):124. doi:
10.1186/s40478-024-01834-8. PMID:
39107839. Case report. ˍ
Tateishi K.
Translational Research
Platform for Malignant Central Nervous System Tumors.
Neurol
Med Chir (Tokyo). 2024 Aug 6. doi:
10.2176/jns-nmc.2024-0078. PMID:
39111869. Observational study. ˍ
Yang J, Lu J, Dong Y, Wei Y, Christian M, Huang J, Kuang H, Cao D.
Revealing the link between gut
microbiota and brain tumor risk: a new perspective from Mendelian
randomization.
Front
Cell Infect Microbiol. 2024 Aug 6;14:1404745. doi:
10.3389/fcimb.2024.1404745. PMID:
39165915. Observational study. ˍ
Balinda HU, Kelly WJ, Kaklamani VG, Lathrop KI, Canola MM,
Ghamasaee P, Sareddy GR, Michalek J, Gilbert AR, Surapaneni P,
Tiziani S, Pandey R, Chiou J, Lodi A, Floyd JR 2nd, Brenner AJ.
Sacituzumab Govitecan in patients with
breast cancer brain metastases and recurrent glioblastoma: a phase
0 window-of-opportunity trial.
Nat
Commun. 2024 Aug 7;15(1):6707. doi:
10.1038/s41467-024-50558-9. PMID:
39112464. Interventional study. ˍ
Dassi N, da Cunha FS, Cappellano AM, de Araujo CA, de Aquino DNS,
de Almeida DB, da Silva NS, Ensina LFC.
Carboplatin
desensitization in the era of target therapies: still worthwhile?
Childs
Nerv Syst. 2024 Aug 7. doi:
10.1007/s00381-024-06564-9. PMID:
39110187. Observational study˰
ˍ
Di Nunno V, Gatto L, Tosoni A, Aprile M, Galvani L, Zappi A,
Foschini MP, Asioli S, Tallini G, De Biase D, Maloberti T,
Bartolini S, Giannini C, Franceschi E.
TP53
mutations and survival in patients with histologically defined
Glioblastoma, IDH-wildtype.
Pathol
Res Pract. 2024 Aug 8;262:155516. doi:
10.1016/j.prp.2024.155516. PMID:
39163733. Observational study˰
ˍ
Holthe J, Boesch P, Kohorst M, Schwartz J, Ferdjallah A.
Persistent hypoxemia in a child with
medulloblastoma following a third autologous stem cell transplant.
Pediatr
Pulmonol. 2024 Aug 8. doi:
10.1002/ppul.27194. PMID:
39115448. Case report˰
ˍ
Moltoni G, Romano A, Capriotti G, Campagna G, Ascolese AM, Romano
A, Dellepiane F, Minniti G, Signore A, Bozzao A.
ASL,
DSC, DCE perfusion MRI and 18F-DOPA PET/CT in differentiating
glioma recurrence from post-treatment changes.
Radiol
Med. 2024 Aug 8. doi:
10.1007/s11547-024-01862-3. PMID:
39117936. Observational study. ˍ
Yan Z, Huang L, Zhang X, Yu X, Huang R.
Anti-tumor
effect of innovative tumor treatment device OM-100 through
enhancing anti-PD-1 immunotherapy in glioblastoma growth.
Sci
Rep. 2024 Aug 8;14(1):18444. doi:
10.1038/s41598-024-67437-4. PMID:
39117725. Laboratory investigation. ˍ
Nair PM, Ramalakshmi R, Devibala M, Saranya M, Sivaranjini S,
Thangavelu R, Mahalingam M.
Integrative
Oncology for High-Grade Glioma: A Case Report on the Combined
Effects of Oncothermia and Complementary Therapies.
Cureus.
2024 Aug 9;16(8):e66492. doi:
10.7759/cureus.66492. PMID:
39246981. Case report. ˍ
Onishi S, Kojima M, Yamasaki F, Amatya VJ, Yonezawa U, Taguchi A,
Ozono I, Go Y, Takeshima Y, Hiyama E, Horie N.
T2-FLAIR
mismatch sign, an imaging biomarker for CDKN2A-intact in
non-enhancing astrocytoma, IDH-mutant.
Neurosurg
Rev. 2024 Aug 9;47(1):412. doi:
10.1007/s10143-024-02632-5. PMID:
39117984. Observational study. ˍ
Bull KS, Stubley S, Freeman A, Liossi C, Darlington AE,
Grootenhuis MA, Hargrave D, Morris C, Walker DA, Kennedy CR.
Experiences of families post treatment
for childhood brain tumours during medical clinic consultations
regarding health-related quality of life, unmet needs and
communication barriers: A qualitative exploration.
Pediatr
Blood Cancer. 2024 Aug 10:e31253. doi:
10.1002/pbc.31253. PMID:
39126369. Observational study. ˍ
El Ouazzani H, Cherradi N.
Primary
mismatch repair-deficient IDH-mutant astrocytoma in child: Unusual
entity.
Int
J Surg Case Rep. 2024 Aug 10;122:110148. doi:
10.1016/j.ijscr.2024.110148. PMID:
39154562. Case report. ˍ
Shin I, Park YW, Sim Y, Choi SH,
Ahn SS, Chang JH, Kim SH, Lee SK, Jain R.
Revisiting
gliomatosis cerebri in adult-type diffuse gliomas: a comprehensive
imaging, genomic and clinical analysis.
Acta
Neuropathol Commun.
2024 Aug 10;12(1):128. doi:
10.1186/s40478-024-01832-w. PMID:
39127694. Observational
study. ˍ